Author: admin

Leptomeningeal Metastases Treatment Market Size in the 7MM was approximately USD 1,300 Million in 2023, estimated DelveInsight

Leptomeningeal Metastases Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Leptomeningeal Metastases Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

 

DelveInsight’s “Leptomeningeal Metastases Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases Market Trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

 

Unlock detailed insights into the Leptomeningeal Metastases Market by downloading the comprehensive report from DelveInsight @ Leptomeningeal Metastases Market

 

Key Takeaways from the Leptomeningeal Metastases Market Report

  • In September 2024:- UNICANCER- The goal of this clinical trial is to evaluate the efficacy of tucatinib and capecitabine in combination with intrathecal trastuzumab on overall survival rate at 12 months in HER2-positive metastatic breast cancer (MBC) patients with proven leptomeningeal evolution and requiring intrathecal therapy.
  • In September 2024:- MedSIR- Multicenter, Single-arm, 3 Cohort, Phase II Trial of HER3-DXd in Patients With Active Brain Metastases From Metastatic Breast Cancer and Non-small Cell Lung Cancer, and in Patients With Leptomeningeal Disease From Advanced Solid Tumors.
  • According to the Nayar et al. (2017), in the United States, 1–8% of cancer patients are diagnosed with LMD, with approximately 110,000 cases of LMD per year in the US. LMD is found in 1–5% of patients with solid tumors, and 1–2% of patients with primary brain tumors. The exact incidence of LMD is difficult to determine, since gross examination at autopsy may overlook signs of LMD, and microscopic pathological inspection may be normal if the seeding is multifocal or if an unaffected area of the CNS is examined.
  • According to the Chamberlain et al., LM occurs in 4±15% of patients with solid tumors, 7±15% of patients with lymphomas, 5±15% of patients with leukemias and 1±2% of patients with primary brain tumors. Solid tumors are disproportionately represented in clinical series of patients with NM due to their high frequency of occurrence, wherein breast (range of tumor-specific occurrence 12±34%), lung (range of tumor-specific occurrence 10±26%), melanoma (range of tumor-specific occurrence 17±25%).
  • According to the Association of Cancer Care (2024), the highest frequency of leptomeningeal metastasis (LM) is observed in melanoma, affecting 22-46% of cases. This is followed by small cell lung cancer, breast cancer, non-small cell lung cancer, and head and neck cancers. Additionally, brain parenchymal metastases may be linked to leptomeningeal disease in as many as 82% of cases.
  • As per the DelveInsight estimates, nearly 70% patients were in low risk patient pool in the United States and nearly 70% patients were taking treatment for leptomeningeal metastases.
  • As per the DelveInsight estimates, in the year 2023, the total diagnosed cases of Leptomeningeal Metastases were ~300,000 cases in the 7MM, which are expected to grow during the study period, i.e., 2020-2034.
  • The leading Leptomeningeal Metastases Companies such as Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, and others.
  • Promising Leptomeningeal Metastases Therapies such as ANG1005, Pertuzumab, Trastuzumab, TY-9591, Trastuzumab deruxtecan, and others.

 

Gain a competitive edge in the Leptomeningeal Metastases Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Leptomeningeal Metastases Treatment Drugs

 

Leptomeningeal Metastases Epidemiology Segmentation in the 7MM

  • Total Leptomeningeal Metastases Diagnosed Cases
  • Total Leptomeningeal Metastases Incident Cases of Different Cancer Types Associated
  • Total Leptomeningeal Metastases Cancer-specific Cases
  • Total Leptomeningeal Metastases Treated Cases

 

Leptomeningeal Metastases Treatment Market

The primary goals of treatment for leptomeningeal metastasis (LM) are to alleviate neurological symptoms, stabilize or improve neurological function, and prolong survival. Prognosis varies significantly based on the primary tumor type and the extent of neurological and systemic disease, making it essential to identify parameters that differentiate poor-risk from good-risk patients to guide therapeutic decisions. For patients with poor prognosis—characterized by a low quality of life, fixed neurological deficits, encephalopathy from extensive LM-brain infiltration, and uncontrolled systemic disease—a palliative approach is recommended, even with LM-directed treatment. Regardless of treatment choices, supportive care is crucial for managing neurological symptoms in all LM patients.

 

Discover key developments and opportunities in the Leptomeningeal Metastases Market. Click here to learn more from DelveInsight’s latest report @ Leptomeningeal Metastases Market Size

 

Leptomeningeal Metastases Emerging Drugs

  • ANG1005: Angiochem

Paclitaxel trevatide (ANG1005) is a peptide-drug conjugate developed by Angiochem, combining paclitaxel with a peptide (Angiopep-2) designed to traverse the blood-brain barrier and blood-cerebrospinal fluid barrier (BCB) via the LRP-1 transport system. This approach aims to overcome the limitations imposed by the efflux pump P-glycoprotein (P-gp), which typically prevents paclitaxel from effectively reaching its target within the central nervous system. ANG1005 is currently under investigation in a Phase III trial (NCT03613181) for the treatment of leptomeningeal carcinomatosis.

 

Leptomeningeal Metastases Market Outlook

The market for leptomeningeal metastases is increasingly optimistic due to rising rates and growing demand for effective treatments. The factors contributing to the growth of the LM market are certain advancements in diagnostic technologies, such as advanced imaging and cerebrospinal fluid analysis, which are crucial for early detection and management of leptomeningeal metastases. The development of novel therapies like Rhenium-186 NanoLiposome and ANG1005, alongside precision radiation techniques, promises to transform treatment options. Despite these advances, challenges remain, such as the lack of approved therapies and the need for more robust clinical trial data.

 

Download DelveInsight’s Leptomeningeal Metastases Market report today and stay ahead in this rapidly evolving field. @ Leptomeningeal Metastases Clinical Trials

 

Scope of the Leptomeningeal Metastases Market Report

  • Coverage- 7MM
  • Leptomeningeal Metastases Companies- Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, and others.
  • Leptomeningeal Metastases Therapies- ANG1005, Pertuzumab, Trastuzumab, TY-9591, Trastuzumab deruxtecan, and others.
  • Leptomeningeal Metastases Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Leptomeningeal Metastases Unmet Needs, KOL’s views, Analyst’s views, Leptomeningeal Metastases Market Access and Reimbursement

 

Download the report to understand which factors are driving Leptomeningeal Metastases Market Trends @ Leptomeningeal Metastases Market Trends

 

Table of Content

1 Key Insights

2 Report Introduction

3 Executive Summary of Leptomeningeal Metastases (LM)

4 Key Events

5 LM Epidemiology and Market Forecast Methodology

6 LM Market Overview at a Glance

7 Disease Background and Overview: LM

8 Treatment and Management

9 Epidemiology and Patient Population of LM in the 7MM

10 Patient Journey

11 Key Endpoints in LM

12 Emerging Therapies

14 LM: Seven Major Market Analysis

15 Unmet Needs

16 SWOT Analysis

17 KOL Views

18 Market Access and Reimbursement

19 Appendix

20 DelveInsight Capabilities

21 Disclaimer

22 About DelveInsight

  

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leptomeningeal Metastases Treatment Market Size in the 7MM was approximately USD 1,300 Million in 2023, estimated DelveInsight

Cystatin C Assay Market Statistics, Trends | Forecast – 2033 | MarketsandMarkets

“The significant players in the cystatin C assay are Siemens Healthcare GmbH (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), Roche Diagnostics Limited. (Switzerland), and Bio-Techne (US)”
The Cystatin C assay industry is poised for significant growth in the near future, driven by a rising demand for accurate and reliable biomarkers in healthcare. Cystatin C, a promising marker of kidney function, is gaining prominence as an alternative to traditional creatinine-based measurements.

Cystatin C Assay Market in terms of revenue was estimated to be worth $377 million in 2023 and is poised to reach $540 million by 2028, growing at a CAGR of 7.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. The growth of this market is majorly driven by growing number of old age population and rising number of kidney diseases. However, high development costs of cystatin C assay may challenge the growth of this market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=186075328

 

UK in European cystatin C assay market to witness the highest shares during the forecast period.

The European cystatin C assay market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. UK is projected to occupy the highest share during the forecast period. Market growth is attributed to the rising geriatric population & chronic diseases, increasing number of accredited clinical & hospital laboratories, growing government healthcare expenditure.

Clinical laboratories in End user’ cystatin C assay market to witness the second highest growth rate during the forecast period.

Based on the end user, cystatin C assay market is segmented into hospitals, clinical laboratories, and pharmaceutical & biotechnology companies & CROs & academic research institutes The clinical laboratories registered the second highest CAGR, due to the growing number of clinical tests performed in laboratories and the increasing number of accredited laboratories, and serving as centralized hubs for diagnostic testing, where a wide array of tests, including cystatin C assays which support market growth.

China dominates the Asia Pacific cystatin C assay market.

The APAC cystatin C assay market is segmented into Japan, China, India, and Rest of Apac. In 2022, China accounted for the largest share of the Asian cystatin C assay market. The large share of China can be attributed to the government efforts to increase awareness about the early detection of diseases and regular health check-ups; rising healthcare expenditure; the increasing number of hospitals and clinical diagnostic laboratories in India and China; and strengthening research base for diagnostic procedures across India, China, and Japan, rising cases of CKD.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=186075328

Cystatin C Assay Market Dynamics:

Drivers:

  1. Rising prevalence of kidney diseases
  2. Growing geriatric population
  3. Recent advancements in chemiluminescence immunoassay technologies
  4. Growth in biotechnology and biopharmaceutical industries
  5. Increasing adoption of POC testing
  6. Supportive government policies

Restraints:

  1. Stringent requirements for approval of cystatin C assay instruments and consumables
  2. High development costs of cystatin C assays

Opportunities:

  1. Growth opportunities in emerging economies
  2. Importance of companion diagnostics
  3. Development of condition-specific biomarkers and tests

Challenge:

  1. Dearth of skilled professionals

Key Market Players of Antibody Drug Conjugates Industry:

The significant players in the cystatin C assay are Siemens Healthcare GmbH (Germany), Thermo Fisher Scientific Inc. (US), Abbott (US), Roche Diagnostics Limited. (Switzerland), and Bio-Techne (US), Randox Laboratories Ltd. (UK), DiaSys Diagnostic Systems GmbH (Germany), and Eurolyser Diagnostica GmbH (Austria)

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=186075328

Cystatin C Assay Market Advantages:

  • Improved Kidney Function Assessment: Cystatin C is considered a more accurate and sensitive biomarker for estimating glomerular filtration rate (GFR) compared to creatinine. It provides a better assessment of kidney function, particularly in cases of mild dysfunction, which can lead to earlier detection and intervention for kidney-related issues.
  • Reduced Variability: Cystatin C levels are less influenced by factors like age, gender, muscle mass, and diet, which can affect creatinine levels. This leads to reduced variability in test results and more consistent and reliable measurements.
  • Early Disease Detection: The Cystatin C assay can detect subtle changes in kidney function, allowing for the early diagnosis of kidney diseases or dysfunction, which is crucial in preventing the progression of renal conditions and associated complications.
  • Broad Clinical Applicability: Cystatin C is not only limited to kidney function assessment; it also has potential in cardiovascular risk prediction, identifying complications in diabetes, and even assessing overall mortality risk. This versatility expands its clinical utility beyond nephrology.
  • Point-of-Care Testing: Advances in Cystatin C assay technology have made point-of-care testing more accessible, providing quicker results that can facilitate immediate clinical decisions and improve patient care.
  • Research and Development Opportunities: Ongoing research into Cystatin C and its applications is opening up opportunities for innovation and the development of new diagnostic tests, which can further expand the market and improve healthcare outcomes.
  • Personalized Medicine: Cystatin C assays can contribute to the growing trend of personalized medicine by helping tailor treatment plans and dosages based on an individual’s renal function, ultimately improving therapeutic efficacy and patient safety.
  • Growing Demand: The increasing prevalence of kidney diseases, in part due to factors like diabetes, hypertension, and an aging population, ensures a sustained demand for Cystatin C assays in clinical settings.
  • Data Integration: Integration of Cystatin C data with electronic health records and other patient data can enhance long-term monitoring and management of kidney function, providing a more comprehensive view of a patient’s health.

Overall, the Cystatin C assay market offers a range of advantages that can significantly enhance the field of clinical diagnostics and improve patient outcomes in the realm of kidney and overall healthcare.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/cystatin-c-assay-market-186075328.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cystatin C Assay Market Statistics, Trends | Forecast – 2033 | MarketsandMarkets

Miss Liz’s Tea Time Returns in October with a Stellar Lineup of Guests: Passion, Power, and Real Conversations

A Month of Insightful Discussions and Personal Stories, Covering Topics from Education and Empowerment to Relationships and Thrilling Tales.

Cornwall, Ontario, Canada – September 24, 2024 – This October, Miss Liz’s Tea Parties are back with a dynamic, fresh lineup of guests, bringing powerful stories, insightful discussions, and a wide range of topics to the table. From personal journeys through illness to heartwarming tales of relationships, empowerment, and education, this season promises to deliver a potent mix of inspiration and deep dives into the human experience. Like the many shades of a Scorpio, Miss Liz’s Tea Parties are packed with intensity, passion, and real talk served with a piping hot dose of T-E-A.

Kicking off on October 3rd at 3:00 PM EST is Risa August, who will share her powerful story, “Border to Border with a Brain Tumor,” discussing her personal journey through illness and recovery. Later that evening, at 7:00 PM EST, Canadian author Joel McKay will join Miss Liz to talk about his thrilling novel, It Came from the Trees.

On October 7th at 3:00 PM EST, returning guest Jeff Rasley will surprise listeners with “A Hitchhiker’s Big Adventure”, offering an exciting look at his journey across the country. October 10th promises engaging discussions with Shannon Hazel at 3:00 PM EST, delving into the world of education with “Teacher EDU”, and later, at 7:00 PM EST, Gary Wietgrefe joins Miss Liz to explore “Human Learning in a One-Room School.” 

Special teatimes this month include a visit from Laura Brennan Ballet on October 14th at 3:00 PM EST. She returns to share insights on “Science of Empowerment”, focusing on science-based approaches to personal growth. The following day, October 15th at 3:00 PM EST, Ayanna Davis, also known as PhenomenallyAutistic, makes her third appearance to discuss “Autistic and Autism”, drawing from her own experiences.

On October 17th, Miss Liz explores the theme of relationships and intimacy. At 3:00 PM EST, two renowned couples, Linda and Charlie Bloom, and Elsbeth Meuth and Freddy Zental share their wisdom on building healthy relationships and understanding true intimacy. Later that evening at 7:00 PM EST, Sean Bridges, known for his work on Stephen King’s Dollar Baby, will discuss his project “Gun Barrel Highway.”

Falling deeper into October, the 24th brings more thought-provoking conversations. At 3:00 PM EST, Carrie Graham will present “COG Learning & Solutions”, an innovative take on cognitive learning. In the evening, at 7:00 PM EST, horror enthusiasts Meg Hafdahl and Kelly Florence will join Miss Liz for a thrilling chat about “Travels of Terror.”

Closing out the month, October 28th at 3:00 PM EST, Jose Pereira will share his intense personal story “From Hero to Villain,” recounting a true hostage situation that changed his life. Finally, on October 29th at 3:00 PM EST, the incredible Joyce Fidler will wrap up the October tea parties with “Evolution of a Baby Boomer,” a reflective conversation on generational changes and the journey of life.

Miss Liz’s Tea Parties are more than just conversations, they are a platform for guests to share their stories, work, and insights in an intimate setting, encouraging listeners to reflect, learn, and grow. Whether it’s through personal battles, relationship advice, or navigating the complex world of education, Miss Liz’s October lineup offers something for everyone.

About Miss Liz’s Tea Parties 

Miss Liz, also known as Elizabeth Jean Olivia Gagnon, hosts captivating teatimes with guests from all walks of life. Known for her ability to dive deep into topics with passion and sensitivity, Miss Liz creates a safe and welcoming space for guests to share their stories. Her podcast is available across major platforms, offering listeners a chance to sip tea and absorb wisdom from her diverse lineup of guests.

Media Contact
Company Name: Miss Liz’s Tea Parties/Teatimes
Contact Person: Elizabeth Jean Olivia Gagnon
Email: Send Email
City: Cornwall
State: Ontario
Country: Canada
Website: http://www.misslizsteatime.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Miss Liz’s Tea Time Returns in October with a Stellar Lineup of Guests: Passion, Power, and Real Conversations

Blockchain Meets Fuel: Fahed Quttainah and Saudi’s Energy Efficiency Center Launch MyFuel.com

Jeddah, Saudi Arabia – MyFuel.com, a new platform at the intersection of energy and blockchain, is set to redefine fuel transactions. This innovative project, spearheaded by Fahed Quttainah, a prominent advocate of blockchain and cryptocurrency, is a collaboration with the Energy Efficiency Center in Saudi Arabia. Together, they aim to transform the way fuel contracts are managed and executed, leveraging blockchain technology for transparency, automation, and security.

Simplifying Fuel Transactions with Smart Contracts

At the core of MyFuel is the use of smart contracts—automated digital agreements that trigger when pre-set conditions, such as fuel prices or delivery dates, are met. This eliminates the need for intermediaries and ensures secure, efficient transactions between buyers and sellers. Every contract is recorded on an immutable blockchain ledger, providing peace of mind to all parties involved.

“We’re modernizing fuel transactions, starting right here in Saudi Arabia, one of the world’s energy powerhouses,” says Fahed Quttainah. “With MyFuel, we’re creating a secure, transparent environment that eliminates inefficiencies and speeds up fuel trading.”

A Visionary Collaboration

This partnership between Fahed Quttainah and the Energy Efficiency Center focuses on using blockchain to streamline fuel trading, benefiting companies, traders, and consumers alike. By automating fuel agreements, the platform also offers tools for carbon offsetting and renewable energy credits, supporting global sustainability goals.

About MyFuel.com

MyFuel is a cutting-edge platform for fuel management, utilizing blockchain to automate contracts and ensure secure transactions. It aligns with Saudi Vision 2030, driving digital transformation and economic diversification in the energy sector.

For more details, contact:

MyFuelFahed Quttainah

info@myfuel.com

https://myfuel.com

https://fahed.io

Media Contact
Company Name: MyFuel
Contact Person: Fahed Quttainah
Email: Send Email
Country: Saudi Arabia
Website: https://myfuel.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Blockchain Meets Fuel: Fahed Quttainah and Saudi’s Energy Efficiency Center Launch MyFuel.com

Ridgeline Construction Roofing & Exteriors Honored as Construction Company of the Year at the 39th Annual Small Business Awards Gala

The Huntsville/Madison County Chamber held its 39th Annual Small Business Awards Gala, honoring local businesses and individuals. Ridgeline Construction Roofing & Exteriors won the Construction Company of the Year award. Lauren Marsh, the company’s president, expressed gratitude for the recognition, highlighting the team’s dedication and community support.

The Huntsville/Madison County Chamber celebrated outstanding local small businesses and individuals during the prestigious 39th Annual Small Business Awards Gala. The event was held at the Von Braun Center’s Saturn Ballroom on Thursday evening, September 12, 2024. Among the distinguished honorees, Ridgeline Construction Roofing & Exteriors proudly received the Construction Company of the Year award.

The Small Business Awards Gala, hosted annually by the Huntsville/Madison County Chamber, is a significant event that acknowledges the remarkable contributions of businesses and individuals within the community. This year, Chambers of Commerce conducted scoring and judging outside the region, ensuring an unbiased selection of awardees.

Lauren Marsh, President of Ridgeline Construction Roofing & Exteriors, graciously accepted the award, stating, “We are deeply honored to be recognized as the Construction Company of the Year. This is a testament to the dedication and hard work of our team and the unwavering support of our community.”

A Chamber representative emphasized the event’s importance, saying, “The Huntsville/Madison County Chamber is proud to celebrate the success of local small businesses and individuals who contribute to the vibrancy of our community. The Small Business Awards Gala is a platform to acknowledge those who go above and beyond, and Ridgeline Construction Roofing & Exteriors is a shining example of excellence.”

Ridgeline Construction Roofing & Exteriors is a family-owned and operated business that takes pride in delivering quality services and products. Their offerings include roofing, siding, gutter installations, and commercial services. With locations in Huntsville, Spanish Fort, Pensacola, and Tampa, Ridgeline is committed to helping its customers across multiple regions.

For more information about Ridgeline Construction Roofing & Exteriors, visit their website at www.ridgelineconstructionhsv.com.

Media Contact
Company Name: Ridgeline Construction
Contact Person: Carina Farr
Email: Send Email
Address:600 Boulevard S SW Suite 104
City: Huntsville
State: AL
Country: United States
Website: https://ridgelineconstructionhsv.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ridgeline Construction Roofing & Exteriors Honored as Construction Company of the Year at the 39th Annual Small Business Awards Gala

Unlock Amazing Travel Experiences with Expert Savings Tips from LoveBitesByCarnie.com

LoveBitesByCarnie.com is excited to unveil a series of travel savings guides tailored to help adventurers maximize their experiences while managing costs. As travel becomes a more essential part of our lives, we understand the importance of exploring the world without breaking the bank. Our mission is to equip readers with the best strategies to make the most of their trips and enjoy unforgettable vacations.

In our latest blog posts, we cover a variety of topics that empower travelers to access the best resources and practical tips. Our commitment to delivering valuable, up-to-date content makes LoveBitesByCarnie.com a go-to destination for savvy travelers.

Exploring Affordable Airbnb Stays

In our detailed guide, “Exploring Affordable Airbnb Stays,” we highlight how travelers can find affordable and unique accommodations through Airbnb. We provide practical advice on securing the best deals, finding last-minute options, and taking advantage of seasonal offers. Whether it’s a quaint cottage or a city apartment, our guide helps readers navigate the platform and find the perfect stay at a great price.

Unlock Amazing Travel Deals with Expedia’s Savings Insights

Next, in “Unlock Amazing Travel Deals with Expedia’s Savings Insights,” we focus on Expedia, one of the leading travel booking sites. We provide tips on how to find lower costs for flights, hotels, and vacation packages through proper timing and by exploring various booking strategies. This comprehensive guide is designed to help travelers optimize their travel budget, allowing them to experience more during their trips.

Fashion and Travel: Looking Great for Less

Traveling often comes with a desire to stay stylish while exploring new destinations. In our blog, “Fashion and Travel: Looking Great for Less,” we share tips on how travelers can find budget-friendly, fashionable clothing for their journeys. From seasonal sales to smart shopping techniques, our readers will discover ways to update their wardrobes without overspending, helping them stay trendy throughout their adventures.

Unique Finds and Memorable Souvenirs

Our content also extends to shopping for unique gifts and memorabilia while traveling. In “Unique Finds and Memorable Souvenirs,” we explore how platforms like Etsy offer a wide range of handmade and vintage items that make for perfect souvenirs. We share tips on how to find the best deals on one-of-a-kind products, ensuring travelers can bring home special items to remember their adventures.

The Importance of Smart Travel Planning

At LoveBitesByCarnie.com, we recognize that careful planning is key to enhancing any travel experience. By providing our readers with expert tips on finding affordable accommodations, discounted activities, and reasonably priced dining, we help them allocate their resources wisely. Our content is crafted to ensure that every aspect of travel is both enjoyable and budget-friendly.

Building a Community of Savvy Travelers

We are dedicated to creating a community of well-informed travelers. LoveBitesByCarnie.com encourages readers to engage with us through comments and feedback, allowing them to share their own travel experiences and tips. Our blog is continuously updated to reflect the latest trends and insights in the travel world, ensuring that our audience stays informed with the most relevant information.

For more travel savings tips and guides, visit LoveBitesByCarnie.com. Let us help you turn your travel dreams into reality without sacrificing your budget!

About LoveBitesByCarnie.com

LoveBitesByCarnie.com is a trusted resource for cat lovers and adventurous souls alike, offering insights into cat care, nutrition, and travel tips for pet owners. Our mission is to empower readers with knowledge and practical savings tips, allowing them to live fulfilling lives both at home and while exploring the world.

Media Contact
Company Name: lovebitesbycarnie.com
Contact Person: Jim Carnie
Email: Send Email
Country: United States
Website: https://lovebitesbycarnie.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Unlock Amazing Travel Experiences with Expert Savings Tips from LoveBitesByCarnie.com

VanMilli Releases Stunning Music Video For Mary Jane

VanMilli has just released a captivating music video for his song “Mary Jane,” which reflects his deep emotional connection to the titular character. In a personal statement, VanMilli describes the track as a heartfelt “letter” to Mary Jane, whom he refers to as the love of his life. He speaks about how she remains by his side through both good times and bad, offering him comfort and relief. VanMilli conveys how being with Mary Jane makes him feel free of pain, and he expresses a desire to wake up every day and experience her presence, again and again.

The music video complements the intimate nature of the song, visually capturing the essence of VanMilli’s bond with “Mary Jane.” The visuals reflect a sense of peace, relaxation, and euphoria, aligning with the emotions he describes in his statement. Throughout the video, VanMilli is seen in serene settings, emphasizing the calm and escape that Mary Jane provides him. 

Fans have responded positively, praising the video’s aesthetic and the raw honesty in the lyrics. “Mary Jane” seems to resonate deeply with listeners who can relate to the theme of finding solace and relief in something or someone that brings consistent support. VanMilli’s expression of love and devotion in this release showcases a personal side of the artist, further deepening his connection with his audience.

VanMilli says, “This is a letter to Mary Jane, the love of my life. She’s always by my side even in my lows and highs. Whenever I’m with her, I feel no pain. Everyday, I just want to wake up and roll up again, again and again.”

About VanMilli:

VanMilli is a multi talented music producer, artist, and songwriter known for his fusion of different genres. His music transcends language barriers and captivates audiences worldwide that allows him to connect with listeners from different cultural backgrounds and foster a sense of unity through his music. VanMilli’s lyrics often touch upon universal themes of love, joy, and self-expression, resonating with audiences on a deep emotional level.

With his unique musical offerings, VanMilli has garnered a growing dedicated fan base that spans across different countries and continents. 

For more details, visit: 

Website:  https://vanmilli.com

YouTube Channel: https://www.youtube.com/vanmilli

Spotify: https://open.spotify.com/artist/1s88hf4zKPipX1ISioKDP0?si=VdbL0GWUThmllD7P_iFxZw

Watch Mary Jane Music Video On YouTube: https://youtu.be/4Nfl2WThbM4

 

Media Contact
Company Name: Brazilian Phonk Media
Contact Person: Josefina Karina
Email: Send Email
Country: Spain
Website: brazilianphonk.co

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: VanMilli Releases Stunning Music Video For Mary Jane

HDAC Inhibitor Treatment Drugs, Clinical Trials, Pipeline Insights, and Companies 2024

DelveInsight’s, “HDAC Inhibitor Pipeline Insight 2024” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in HDAC Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore our comprehensive HDAC Inhibitor Pipeline Report to stay informed about the latest advancements. Download copy now @ HDAC Inhibitor Pipeline Outlook

 

Key Takeaways from the HDAC Inhibitor Pipeline Report

  • In January 2024:- Xynomic Pharmaceuticals Inc.-This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a “one week on, one week off” schedule. Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER).
  • DelveInsight’s HDAC Inhibitor pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for HDAC Inhibitor treatment.
  • The leading HDAC Inhibitor Companies such as Italfarmaco, Amylyx Pharmaceuticals, Chong Kun Dang pharmaceuticals, Cereno Scientific, Xynomic Pharmaceuticals, HUYA Bioscience, Recursion Pharmaceuticals Inc., Regenacy Pharmaceuticals, Acrotech Biopharma, Aphios Corporation, and others.
  • Promising HDAC Inhibitor Therapies such as Abexinostat, Givinostat, AMX0035, CKD-506, CS1, CS014, and others.

 

Dive into our HDAC Inhibitor Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ HDAC Inhibitor Treatment Therapies

 

HDAC inhibitors Emerging Drugs

  • Givinostat: Italfarmaco

Givinostat (ITF2357) is an orally bioavailable hydroxymate inhibitor of histone deacetylase (HDAC) with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. Givinostat inhibits class I and class II HDACs, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. At low nonapoptotic concentrations, this agent inhibits the production of pro-inflammatory cytokines such as tumor necrosis factor (TNF), interleukin-1 (IL-1), IL-6, and interferon-gamma. This reduces the expression of tumor necrosis factor (TNF), interleukin 1α and β, and interleukin. It has also been shown to activate the intrinsic apoptotic pathway, inducing apoptosis in hepatoma cells and leukemic cells. This agent may also exhibit anti-angiogenic activity, inhibiting the production of angiogenic factors such as IL-6 and Vascular Endothelial Cell Growth Factor (VEGF) by bone marrow stromal cells. Currently, the drug is in the Phase III stage of its development for the treatment of Polycythemia Vera.

  • AMX0035: Amylyx Pharmaceuticals

AMX0035 is an oral, fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO; also known as ursodoxicoltaurine outside of the US). AMX0035 was designed to slow or mitigate neurodegeneration by targeting endoplasmic reticulum (ER) stress and mitochondrial dysfunction, two connected central pathways that lead to cell death and neurodegeneration. The company believes that the proprietary combination of PB and TURSO and their complementary mechanisms of action will allow to synergistically target abnormal cell death to better prevent neurodegeneration than treatment targeted at either mechanism of action alone. AMX0035 is being studied as a potential treatment for Wolfram syndrome and progressive supranuclear palsy, two neurodegenerative disease. Currently, the drug is in the Phase III stage of its development for the treatment of Progressive Supranuclear Palsy.

  • CKD-506: Chong Kun Dang pharmaceuticals

CKD-506 is a novel selective histone deacetylase 6 (HDAC6) inhibitor developed by Chong Kun Dang Pharmaceuticals. It is primarily being investigated for its therapeutic potential in treating autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus (SLE). CKD-506 functions by selectively inhibiting HDAC6, an enzyme involved in the regulation of inflammatory responses. This inhibition leads to the suppression of inflammatory cytokines such as TNF-α and type 1 interferons, which are significant contributors to the pathogenesis of various autoimmune conditions. Studies have shown that CKD-506 can improve the function of regulatory T cells (Tregs) and enhance gut barrier function, further supporting its role in reducing inflammation. It is currently in Phase II for Rheumatoid Arthritis.

  • CS1: Cereno Scientific

The drug candidate CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed as a treatment for the rare disease PAH. CS1 has the potential to be an effective, safe and disease-modifying drug. CS1’s unique efficacy profile fits well with the pathogenetic mechanisms of PAH and is believed to be able to address today’s major unmet need for better treatment alternatives. The aim of CS1’s development is to offer improved quality of life and prolonged life with CS1 for patients with PAH. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Pulmonary Arterial Hypertension.

  • CS014: Cereno Scientific

The investigational drug candidate CS014 belongs to Cereno’s HDAC inhibitor program, capitalizing on the principle of epigenetic modulation. The innovative drug candidate represents a novel approach to antithrombotic treatment without an increased risk of bleeding. CS014 is a new chemical entity with a multi-modal mechanism of action as an epigenetic modulator – regulating platelet activity, local fibrinolysis, and clot stability for the prevention of thrombosis without increasing the risk of bleeding, as documented in preclinical studies. Given the potential for the disease-modifying properties seen with HDAC inhibition, additional cardiovascular benefits of CS014 may be expected, including amelioration of inflammation, fibrosis, vascular remodeling and elevated blood pressure. HDAC inhibition as a therapy to avoid thrombosis could fundamentally change the thrombosis prevention landscape and meet a major unmet medical need. It is currently in Phase I for Thrombosis prevention.

 

Download the HDAC Inhibitor Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ HDAC Inhibitor Clinical Trials Assessment

 

HDAC inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

HDAC Inhibitor Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Dive into our detailed HDAC Inhibitor Pipeline Report to discover groundbreaking advancements shaping the future of cancer treatment @ HDAC Inhibitor Products, Companies, and Unmet Needs

Scope of the HDAC Inhibitor Pipeline Report

  • Coverage- Global
  • HDAC Inhibitor Companies- Italfarmaco, Amylyx Pharmaceuticals, Chong Kun Dang pharmaceuticals, Cereno Scientific, Xynomic Pharmaceuticals, HUYA Bioscience, Recursion Pharmaceuticals Inc., Regenacy Pharmaceuticals, Acrotech Biopharma, Aphios Corporation, and others.
  • HDAC Inhibitor Therapies- Abexinostat, Givinostat, AMX0035, CKD-506, CS1, CS014, and others.
  • HDAC Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • HDAC Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Gain valuable insights into emerging therapies and innovations with our HDAC Inhibitor Pipeline Report @ HDAC Inhibitor Market Drivers and Barriers, Future Perspectives and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. HDAC inhibitors : Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. HDAC inhibitors – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Givinostat: Italfarmaco
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CKD-506: Chong Kun Dang pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. CS014: Cereno Scientific
  15. Preclinical Stage Products
  16. Drug Name: Company Name
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. HDAC inhibitors – Collaborations Assessment- Licensing / Partnering / Funding
  20. HDAC inhibitors – Unmet Needs
  21. HDAC inhibitors – Market Drivers and Barriers
  22. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HDAC Inhibitor Treatment Drugs, Clinical Trials, Pipeline Insights, and Companies 2024

Surgical Robots Market to Surge from USD 11.1 Billion to USD 23.7 Billion by 2029, Growing at a CAGR of 16.5%

“Stryker Corporation, a leading medical device company, operates across three main segments: Orthopaedics, MedSurg, and Neurotechnology and Spine.”
The global surgical robots market is anticipated to grow from USD 11.1 billion in 2024 to USD 23.7 billion by 2029, at a compound annual growth rate (CAGR) of 16.5%.

The global surgical robots market is anticipated to grow from USD 11.1 billion in 2024 to USD 23.7 billion by 2029, at a compound annual growth rate (CAGR) of 16.5%. Surgical robots enhance surgical precision, control, and flexibility, consisting of robotic arms, specialty tools, a camera system, and a control console. Factors driving market growth include the increasing adoption of minimally invasive procedures, technological advancements, and the need for precise surgical outcomes. However, high costs associated with advanced technology, maintenance, and training are significant barriers. Opportunities lie in the growing use of surgical robots in Ambulatory Surgical Centers (ASCs) due to their benefits in reducing recovery times and healthcare costs. Challenges include the potential for surgical errors due to technical issues or operator mistakes. Key market players include Intuitive Surgical, Medtronic, and Stryker. North America leads the market due to its advanced healthcare infrastructure and high investment in medical technology. The market is segmented by offering, application, end user, and region, with instruments & accessories, general surgery, and hospitals & clinics being prominent segments.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=256618532

Market Segmentation by Offering

The surgical robots market is categorized into instruments & accessories, robotic systems, and services. In 2023, the instruments and accessories segment is projected to dominate the market. These components are essential for enhancing the functionality, precision, and flexibility of robotic surgical systems. They include specialized tools like forceps, scissors, and suturing devices, which are crucial for various minimally invasive procedures. The demand for these instruments is driven by their continuous need for replacement and upgrades due to wear and tear and advancements in technology.

Market Segmentation by Application

The surgical robots market is segmented into general surgery, gynecological surgery, orthopedic surgery, urological surgery, neurosurgery, microsurgery, otological surgery, and others. General surgery is expected to hold the largest share in 2023 due to its broad application and the adaptability of robotic systems in various procedures. Robotic systems, such as the da Vinci Surgical System, provide enhanced precision, control, and visibility, contributing to improved patient outcomes and faster recovery, thus sustaining the demand for robotic systems in general surgery.

Market Segmentation by End User

Hospitals and clinics are anticipated to be the largest end users of surgical robots in 2023. These facilities are major adopters due to their need for advanced surgical technologies that improve precision, expedite patient recovery, and reduce risks associated with complex procedures. Hospitals and clinics have invested heavily in robotic systems to leverage their benefits and cost-effectiveness, driven by their existing infrastructure, skilled staff, and financial resources.

Regional Insights

In 2023, North America is expected to lead the surgical robots market in both market share and CAGR. The region’s dominance is attributed to its well-established healthcare infrastructure, high acceptance of cutting-edge technology, and substantial investment in healthcare innovation. Major medical device companies involved in the development and commercialization of surgical robots are based in North America, and the region’s favorable reimbursement policies and robust regulatory environment further support its market leadership.

Key Market Players

Key players in the surgical robots market include Intuitive Surgical (US), Stryker (US), Medtronic (Ireland), Smith+Nephew (UK), Zimmer Biomet (US), Asensus Surgical (US), Siemens Healthineers (Germany), CMR Surgical (UK), Johnson & Johnson (US), Renishaw Plc (UK), Avateramedical GmbH (Germany), Brainlab AG (Germany), Think Surgical (US), Medicaroid Corporation (Japan), Globus Medical, Inc. (US), Corin Group (UK), Ecential Robotics (France), Titan Medical, Inc. (Canada), TINAVI Medical (China), Monteris (US), Microsure (Netherlands), Medical Microinstruments (US), Momentis Innovative Surgery (Israel), Distalmotion (Switzerland), and Novus Arge (Turkey). These companies are expanding their market presence through strategies such as product launches, acquisitions, collaborations, agreements, and market expansion.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=256618532

Intuitive Surgical

Intuitive Surgical is a prominent player known for its robotic-assisted surgical systems, including the da Vinci system, which was the first FDA-cleared robotic system for laparoscopic surgery in 2000. The da Vinci system is versatile, supporting procedures such as prostatectomy, hysterectomy, and hernia repair. The company’s products are distributed through direct sales channels in the US and Europe. As of 2023, approximately 659 da Vinci systems were under operating lease arrangements, with 355 on usage-based leases. In India, over 800 robotically assisted surgeons and more than 100 da Vinci systems are operational in major private and public institutions.

Stryker Corporation

Stryker Corporation, a leading medical device company, operates across three main segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. It offers a wide range of products, including implants, surgical instruments, and navigation systems. The company entered the surgical robots market through its acquisition of MAKO Surgical in 2013. Stryker’s surgical robots are part of its Orthopaedics and Spine segment. With 30 manufacturing facilities globally, Stryker maintains a strong presence in the US, Canada, Europe, Japan, and Latin America.

Medtronic Plc

Medtronic Plc ranks third in the surgical robots market. The company, formed after the 2015 acquisition of Covidien plc, provides a broad spectrum of medical devices across various segments, including Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The Surgical Innovations segment, part of its Medical Surgical division, includes surgical robots. Medtronic operates in over 150 countries, serving hospitals, clinics, and other healthcare institutions globally.

For more information, inquire now! Inquire Now

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/surgical-robots-market-256618532.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Surgical Robots Market to Surge from USD 11.1 Billion to USD 23.7 Billion by 2029, Growing at a CAGR of 16.5%

UVKXE: Empowering Institutional and Professional Traders Through API Enhancement

UVKXE, a prominent cryptocurrency exchange, has announced a significant upgrade to its API capabilities. This technological advancement aims to provide comprehensive support to clients and developers, marking substantial progress in UVKXE to enhance technological offerings and optimize customer service. By delivering highly customizable features, UVKXE is well-positioned to meet the demands of quantitative programming and innovative application development.

The API enhancement is a strategic initiative by UVKXE to strengthen collaboration with high-frequency quantitative clients. UVKXE with its high-performance trading system has already demonstrated exceptional capability in handling large-scale high-frequency trading. The recent API upgrade specifically focuses on optimizing asset management functionalities for clients, further solidifying the advantageous position of UVKXE in the high-frequency trading market. This initiative is expected to assist clients in achieving superior investment returns amid the dynamic cryptocurrency market.

Notably, the upgrade also includes enhanced security for API interfaces. By adopting the latest encryption technology and implementing multi-layered security measures, UVKXE provides robust protection for user assets and information, reinforcing its commitment to secure trading and financial management services.

UVKXE is dedicated to offering compliant, secure, and convenient cryptocurrency trading and financial management services. Its comprehensive security system has received widespread industry recognition. The API upgrade will equip professional traders and institutional investors on the UVKXE platform with powerful tools to effortlessly execute their strategies. Comprehensive API support is expected to attract more talented developers, fostering innovation in cryptocurrency trading.

Through continuous technological innovation and service enhancements, UVKXE ensures that developers can efficiently execute strategies and deploy applications on its platform. This aligns with UVKXE goal of building an open and mutually beneficial trading ecosystem.

The API upgrade by UVKXE represents a milestone in its technological evolution and sends a clear message to the industry: UVKXE is committed to providing unwavering support to traders and developers, inspiring users and promoting the prosperity of the global cryptocurrency market. As UVKXE continues to introduce new features and services, global users on the UVKXE exchange can expect not only a compliant, secure, and convenient trading experience but also the potential for optimal returns and expansive growth opportunities.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: UVKXE CRYPTO TECH CO.,LTD
Contact Person: Mayang
Email: Send Email
Country: United States
Website: https://www.uvkxe.co